| Antigen: | CD9 |
| Clone: | P1/33/2 |
| Subclass | IgG1 |
| Species Raised In: | Mouse |
| Immunogen: | Acute lymphoblastic leukaemia cells |
| Cross Reactivity: | Human |
| Applications: | FACS, Frozen |
| Growth Conditions: | RPMI 1640 + 10% FCS + penicillin (100U/ml) + streptomycin (100mg/l) + glutamine (2mM) + HAT |
| Fusion Partner: | NS1 |
| Relevance: | CD9 antigen is a glycoprotein expressed on the surface of developing B lymphocytes, platelets, monocytes, eosinophils, basophil, stimulated T lymphocytes and neurons and glial cells in the peripheral nervous system. CD9 mediates platelet aggregation and activation via FcgRIIa. It may play a role in cell migration.Antibodies against CD9 have utility in characterisation of acute leukaemias and in some cases AML and for functional studies on platelets |
| References: | Jennings LK, Crossno JT, White MM (1993) CD9 cluster workshop report: cell surface binding and functional analysis. In Schlossman SF, et al (eds) Leucocyte Typing V, Vol 2, Oxford University Press, Oxford, New York and Tokyo, p 1249-51 |
| Notes: | Please note this cell line has not been weaned out of HAT. Ultroser G can be used at 1% if the cells are not growing well. |
© Cancer Research Technology 2012